Journals / Akdeniz Tıp Dergisi / 2019 / Cilt: 5 - Sayı: 1

Fabry Disease: A Review

Fabry Hastalığı: Derleme

Pages
21–31
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The clinician must be alert to not miss the disorder as it can have various manifestations

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The etiology of chronic kidney disease is multifactorial but diabetes mellitus and hypertension are the main factors.
📊
Key Findings & Data:One of the rare causes is Fabry disease.
💡
Conclusion & Impact:The clinician must be alert to not miss the disorder as it can have various manifestations
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Fabry hastalığı · Alfa-Galaktozidaz A · GLA gen mutasyonu

Abstract

The etiology of chronic kidney disease is multifactorial but diabetes mellitus and hypertension are the main factors. One of the rare causes is Fabry disease. Fabry disease is often overlooked in the diagnosis due to the low awareness of the disease, its rare occurrence, and the various clinical variants. The disease has X-related recessive inheritance and all men who carry the diseased X gene are therefore affected. The disease exhibits mosaicism in women due to the ionization in females. Fabry disease is detected by enzyme activity, gene analysis evaluation, and the measurement of accumulated metabolites in the blood or tissue. Enzyme replacement therapy and supportive therapy are used for the treatment. The clinician must be alert to not miss the disorder as it can have various manifestations

Özet

Kronik böbrek hastalığı etiyolojisinde diyabetes mellitus ve hipertansiyon başta olmak üzere birçok neden vardır. Etiyolojide yer alan nadir görülen nedenlerden biri de Fabry hastalığıdır. Fabry hastalığı farkındalığı düşük olması, nadir görülmesi ve çeşitli klinik varyantları olması nedeniyle sıklıkla tanıda gözden kaçmaktadır. Hastalık X’e bağlı resesif geçtiği için geni taşıyan tüm erkekler etkilenir. Kadınlarda iyonizasyon olması nedeniyle kadınların hastalıktan etkilenmesi mozaizm gösterir. Fabry hastalığı tespitinde enzim aktivitesi, gen analiz değerlendirilmesi ve biriken metabolitlerin kanda veya dokularda ölçümü kullanılır. Tedavisinde enzim replasman tedavisi ve destek tedavi uygulanır. Hastalığın kliniğe yansıması farklı olduğundan klinisyen tanıyı gözden kaçırmamak için dikkatli olmalıdır

🔖

Cite This Article

SARI, F., ATAŞ, E. N. S., ÇETİNKAYA, R. (2022). Fabry Disease: A Review. Akdeniz Tıp Dergisi, Cilt: 5 - Sayı: 1, 21–31. https://ajindex.com/articles/434371

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Mcphee SJ, Papadakis M. Current Medical Diagnosis and Treatment 2016. Müftüoğlu E (ed). 54. baskı. Ankara: Akademisyen Kitabevi, 2016: 890-929
  2. Germain D. Fabry disease. Orphanet J Rare Disease 2010;5:30
  3. Schiller PI, Itin PH. Angiokeratomas: An update. Dermatology 1996; 193(4):275-82
  4. Gaggl M, El-Hadi S, Aigner C. Sunder-Plassmann G. The renal history of fabry disease. G Ital Nefrol 2016; 33 Suppl 66:S66.14
  5. De Groot WP. Angiokeratoma corporis diffusum Fabry. Amsterdam Dermatologica 1968; 136(5):432-3
  6. Kılıç M. Fabry hastalığının tarihçesi. Türkiye Klinikleri J Pediatr 2012; 21 Suppl 1:1-6
  7. Mayes JS, Scheerer JB, Sifers RN, Donaldson ML. Differential assay for lysosomal alpha-galactosidases in human tissues and its application to Fabry’s disease. Clin Chim Acta 1981; 112(2):247-51
  8. Schiffmann R, Murray GJ, Treco D, Daniel P, SellosMoura M, Myers M,Quirk M J, Zirzow G C, Borowski M, Loveday K, Anderson T, Gillespie F, Oliver K L, Jeffries N O, Doo E, Liang T J, Kreps C, Frei K, Crutchfield K, Selden R F, Brady RO. Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci USA 2000; 97(1): 365-70
  9. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders, JAMA 1999; 281(3):249-54
  10. MacDermot KD, Holmes A, Miners AH. AndersonFabry disease: Clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 2001; 38(11):769-75
  11. Lin HY, Chong KW, Hsu JH, Yu HC, Shih CC, Huang CH, Lin SJ, Chen CH, Chiang CC, Ho HJ, Lee PC, Kao CH, Cheng KH, Hsueh C, Niu DM. High incidence of the cardiacvariant of Fabry disease revealed by newbornscreening in the Taiwan Chinese population. Circ Cardiovasc Genet 2009; 2(5):450-6
  12. Uçar SK. Fabry hastalığı (Ege Üniversitesi Tıp Fakültesi tarama sonuçları). J LSD 2010; 2:35
  13. Barba-Romero MÁ, Rivera-Gallego A, Pintos-Morell G; Spanish FOS-Study Group. Fabry disease in Spain: description of Spanish patients and a comparison with other European countries using data from the Fabry Outcome Survey (FOS). Int J Clin Pract 2011; 65(8):903-10
  14. Tsuboi K, Suzuki S, Nagai M. Descriptive epidemiology of Fabry disease among beneficiaries of the Specified Disease Treatment Research Program in Japan. J Epidemiol 2012; 22(4):370-4
  15. Burton BK, Charrow J, Hoganson GE, Waggoner D, Tinkle B, Braddock SR, Schneider M, Grange DK, Nash C, Shryock H, Barnett R, Shao R, Basheeru